项目由麻省理工学院Robert S. Langer 博士和Shuguang Zhang博士为技术负责人，
利用创新的“QTY码”修饰蛋白作为新型治疗靶点
2019年5月21日新泽西州Freehold——国际领先的细胞生物技术公司Avalon Globocare (NASDAQ：AVCO) 今天宣布，公司已与麻省理工学院（MIT）签署了一项赞助研究和授权协定，将利用人工智慧（AI） 增强蛋白设计“QTY 码”为细胞治疗生成新型治疗靶点。 “QTY 码”这一突破性技术大幅提升了设计肽和蛋白质的溶解度，从而扩大了针对癌症和其他疾病的选定治疗靶点的范围。 Avalon将与麻省理工学院Robert S. Langer 博士和Shuguang Zhang博士共同启动研究和研发，针对细胞因子释放综合征（Cytokine Release Syndrome）、T细胞白血病（T-cell leukemia）的下一代疗法，以及为细胞免疫治疗重新设计免疫细胞的新方法。
Avalon GloboCare的CEO兼总裁David Jin博士表示：“我们非常荣幸能与麻省理工学院合作，在Langer 博士和Zhang 博士的领导下，研发和应用这种前沿的AI增强蛋白设计QTY码技术。这将极大地丰富我们上游的研发创新，并与我们最先进的生产制备以及下游的针对细胞治疗临床患者的管理形成无缝整合。”
Avalon GloboCare Corp.（NASDAQ: AVCO）是一家国际领先的细胞技术开发公司，致力于开发和转化具有创新性、变革性的外泌体和细胞治疗技术。Avalon也提供战略咨询和技术合作服务，以协助促进其客户在技术开发领域的发展，提高其在本国和全球医疗市场的竞争力。通过子公司GenExosome Technologies Inc.和Avactis Biosciences Inc.，Avalon在基于外泌体的诊断(“液体活检”) 、细胞免疫治疗(包括CAR-T/CAR-NK) 和再生医学领域建立了领先地位。
Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of the press release.
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
[email protected]
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
[email protected]
